A Phase 2 interventional study of Pemetrexed and Cisplatin in Non-Small-Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 12 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-02-17.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 8 of them phase 3. Cisplatin · Carcinoma, Non-Small-Cell Lung.
Among the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung, this one is the 55th largest by enrollment of the 198 interventional ones that give a count, is one of 8 that started in 2006, is one of 115 in phase 2, and was the 74th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →13 of the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
The Affiliated Hospital of Qingdao University · Sites in China
Ages 18–75
AstraZeneca · Sites in United States, Belgium, Canada and 9 more countries
Ages 18–95
Hunan Province Tumor Hospital · Sites in China
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
213 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 132 · Phase 3 47 · Phase 4 3
First in 1994; this study’s year is marked. 8 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 133 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 58 across the 198 interventional studies. Of the 159 that completed or were terminated, 62 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 213 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 60th largest by enrollment of the 139 interventional ones that give a count, is one of 10 that started in 2006, is one of 73 in phase 2, and was the 45th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
4 of the studies testing cisplatin in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT02889666Shanghai Jiao Tong University School of MedicineA Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer | 2026-12 |
| NCT04253964Wake Forest University Health SciencesPilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 213 studies testing cisplatin in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This is a two-arm, parallel, open-label, Phase 2 multicenter study of pemetrexed as first line combination therapy with either cisplatin or carboplatin in the palliative setting of stage IIIb and IV non-small cell lung cancer patients. Approximately 130 patients will be included in about 15 centers in Germany and randomized to one of the above treatment regimens in a 1:1 ratio. Chemotherapy will be administered over a maximum of six cycles with a standard length of 21 days. Primary objective will be the Progression Free Survival Time of patients as assessed in both treatment arms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pemetrexed · Drug: Cisplatin
Drug: Pemetrexed · Drug: Carboplatin
500 mg/m2, intravenous (IV), every 21 days x 6 cycles
Also known as: LY231514, Alimta
75 mg/m2, intravenous (IV), every 21 days x 6 cycles
Area under the concentration curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate)
For this study, we used the exponential distribution (assumption done for the calculation of the sample size) to estimate the PFS rate. The PFS rate (%) and the 95% confidence intervals were calculated based on the following formula: exp(-6 λ) ± 1.96 \* exp(-6 λ) \* (-6 λ)/√r. Where λ was calculated based on the Maximum-Likelihood estimator for ln(λ) as given by (Collett 2003): ln(λ) = ln\[ r / ∑ti \] with r = number of patients with events up to 6 months, ti = survival time of patient i (i=1,...,n), event or censored up to 6 months, and n= total number of patients per treatment group.
Time frame: Randomization to Month 6
Overall Survival
Defined as the time from randomization to the date of death from any cause.
Time frame: Randomization to date of death from any cause (up to 1 year)
Number of Participants With Tumor Response (as Basis for Response Rate)
Best overall response was evaluated using RECIST Criteria which define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatment. CR: complete response, disappearance of all target lesions; PR: partial response, 30% decrease in sum of the longest diameter of target lesions; PD: progressive disease, 20% increase in sum of the longest diameter of target lesions; SD: stable disease, small changes not meeting above criteria. Response Rate: number of participants with response(CR+PR)per total population, multiplied by 100 to give a percentage.
Time frame: Every 6 weeks for 6 months during the treatment period, and every 3 months during the follow-up period, until disease progression
Time to Treatment Failure (TTF)
Defined as time from randomization to the first date of disease progression, death due to any cause, or early discontinuation of treatment (any reason), whichever occurred first
Time frame: Randomization to stopping of treatment, progression, death or initiation of further chemotherapy, whichever occurs first (up to 1 year)
Pharmacology Toxicities
Number of patients experiencing Grade 3 or 4 hematologic and non-hematologic adverse events (AEs) possibly related to study drug or protocol procedures in this study (a subset of those listed in the AE Module). AEs were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. A grading (severity) scale is provided for each adverse event term. Grades range from 0 (none) to 5 (death). Grade 3 AEs are severe and undesirable; Grade 4 AEs are life-threatening or disabling.
Time frame: Every 21-day cycle for up to 6 cycles
| Milestone | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin |
|---|---|---|
| Started | 66 | 67 |
| Received treatment | 65 | 65 |
| Completed | 28 | 32 |
| Not completed | 38 | 35 |
| Withdrew: Progressive disease | 13 | 20 |
| Withdrew: Adverse event | 11 | 4 |
| Withdrew: Physician decision | 7 | 3 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| Withdrew: Death - related to study drug | 1 | 2 |
| Withdrew: Death due to study disease | 2 | 1 |
| Withdrew: Death due to adverse event | 0 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
For this study, we used the exponential distribution (assumption done for the calculation of the sample size) to estimate the PFS rate. The PFS rate (%) and the 95% confidence intervals were calculated based on the following formula: exp(-6 λ) ± 1.96 \* exp(-6 λ) \* (-6 λ)/√r. Where λ was calculated based on the Maximum-Likelihood estimator for ln(λ) as given by (Collett 2003): ln(λ) = ln\[ r / ∑ti \] with r = number of patients with events up to 6 months, ti = survival time of patient i (i=1,...,n), event or censored up to 6 months, and n= total number of patients per treatment group.
| percentage | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin |
|---|---|---|
| Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate) | 52.8 (40.3 to 65.3) | 39.3 (27.8 to 50.8) |
Defined as the time from randomization to the date of death from any cause.
| months | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin |
|---|---|---|
| Overall Survival | 11.7 (9.2 to 14.9) | 8.9 (6.0 to 12.2) |
Best overall response was evaluated using RECIST Criteria which define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatment. CR: complete response, disappearance of all target lesions; PR: partial response, 30% decrease in sum of the longest diameter of target lesions; PD: progressive disease, 20% increase in sum of the longest diameter of target lesions; SD: stable disease, small changes not meeting above criteria. Response Rate: number of participants with response(CR+PR)per total population, multiplied by 100 to give a percentage.
| participants | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin |
|---|---|---|
| Partial Response | 21 | 13 |
| Stable Disease | 31 | 32 |
| Disease Progression | 7 | 15 |
| Unknown/Not Done | 6 | 5 |
Defined as time from randomization to the first date of disease progression, death due to any cause, or early discontinuation of treatment (any reason), whichever occurred first
| months | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin |
|---|---|---|
| Time to Treatment Failure (TTF) | 3.0 (2.3 to 4.6) | 3.4 (2.3 to 4.8) |
Number of patients experiencing Grade 3 or 4 hematologic and non-hematologic adverse events (AEs) possibly related to study drug or protocol procedures in this study (a subset of those listed in the AE Module). AEs were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. A grading (severity) scale is provided for each adverse event term. Grades range from 0 (none) to 5 (death). Grade 3 AEs are severe and undesirable; Grade 4 AEs are life-threatening or disabling.
| participants | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin |
|---|---|---|
| Any Grade 3/4 Toxicity | 29 | 36 |
| Grade 3/4 Leucopenia | 8 | 12 |
| Grade 3/4 Neutropenia | 11 | 17 |
| Grade 3/4 Anemia | 5 | 7 |
| Grade 3/4 Thrombocytopenia | 2 | 11 |
| Grade 3/4 Nausea | 3 | 5 |
| Grade 3/4 Vomiting | 2 | 1 |
| Grade 3/4 Fatigue | 2 | 2 |
| Grade 3/4 Anorexia | 1 | 2 |
| Grade 3/4 Urinary Tract Infection | 0 | 2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed + Cisplatin | — | 22/65 (33.8%) | 61/65 (93.8%) |
| Pemetrexed + Carboplatin | — | 28/65 (43.1%) | 59/65 (90.8%) |
| Event | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/65 | 5/65 |
| AnaemiaBlood and lymphatic system disorders | 3/65 | 3/65 |
| NauseaGastrointestinal disorders | 2/65 | 3/65 |
| PneumoniaInfections and infestations | 3/65 | 2/65 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/65 | 3/65 |
| Cardiac failureCardiac disorders | 1/65 | 2/65 |
| VomitingGastrointestinal disorders | 2/65 | 2/65 |
| Renal failure acuteRenal and urinary disorders | 2/65 | 1/65 |
| Deep vein thrombosisVascular disorders | 0/65 | 2/65 |
| Anaemia of malignant diseaseBlood and lymphatic system disorders | 0/65 | 1/65 |
| Event | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin |
|---|---|---|
| NauseaGastrointestinal disorders | 42/65 | 27/65 |
| NeutropeniaBlood and lymphatic system disorders | 18/65 | 25/65 |
| FatigueGeneral disorders | 25/65 | 24/65 |
| LeukopeniaBlood and lymphatic system disorders | 17/65 | 24/65 |
| VomitingGastrointestinal disorders | 24/65 | 8/65 |
| AnaemiaBlood and lymphatic system disorders | 12/65 | 19/65 |
| ThrombocytopeniaBlood and lymphatic system disorders | 9/65 | 18/65 |
| ConstipationGastrointestinal disorders | 17/65 | 11/65 |
| AnorexiaMetabolism and nutrition disorders | 16/65 | 10/65 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 13/65 | 10/65 |
| Age Continuous(years) | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin | Total |
|---|---|---|---|
| Mean | 62.3 ± 8.43 | 62.4 ± 7.51 | 62.4 ± 7.95 |
| Sex: Female, Male(Participants) | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin | Total |
|---|---|---|---|
| Female | 23 | 19 | 42 |
| Male | 42 | 46 | 88 |
| Race/Ethnicity, Customized(participants) | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin | Total |
|---|---|---|---|
| Caucasian | 65 | 65 | 130 |
| Region of Enrollment(participants) | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin | Total |
|---|---|---|---|
| Germany | 65 | 65 | 130 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin | Total |
|---|---|---|---|
| 0 - Fully Active | 40 | 45 | 85 |
| 1 - Ambulatory, Restricted Strenuous Activity | 25 | 20 | 45 |
| Histopathology(participants) | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin | Total |
|---|---|---|---|
| Squamous Cell Carcinoma | 12 | 13 | 25 |
| Adenocarcinoma | 38 | 44 | 82 |
| Large Cell Carcinoma | 6 | 3 | 9 |
| Mixed Cell Carcinoma | 0 | 1 | 1 |
| Bronchioalveolar Carcinoma | 0 | 1 | 1 |
| NSCLC, Not Otherwise Specified | 9 | 3 | 12 |
| Presence of Bone and Brain Metastases(participants) | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin | Total |
|---|---|---|---|
| Bone Metastases | 14 | 11 | 25 |
| Brain Metastases | 2 | 1 | 3 |
| Smoking Status(participants) | Pemetrexed + Cisplatin | Pemetrexed + Carboplatin | Total |
|---|---|---|---|
| Never Smoked | 9 | 7 | 16 |
| Past Smoker | 41 | 42 | 83 |
| Current Smoker | 15 | 16 | 31 |
3 further baseline measures are reported on the registry.
The record gives a start of Nov 2006, a primary completion of Dec 2008 and a completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cisplatin · Carboplatin
Carcinoma, Non-Small-Cell Lung →